GLUE · Categories · Form 4

GLUE - SEC Form 4 insider transactions

Monte Rosa Therapeutics Inc. (GLUE) sec form 4 insider transactions - real-time wire coverage filtered to Form 4 only.

Recent Form 4 for GLUE

• 11d
  SEC Form 4 filed by Warmuth Markus

  4 - Monte Rosa Therapeutics, Inc. (0001826457) (Issuer)
• 16d
  SEC Form 4 filed by Nickson Philip

  4 - Monte Rosa Therapeutics, Inc. (0001826457) (Issuer)
• 19d
  SEC Form 4 filed by Bowen Matthew

  4 - Monte Rosa Therapeutics, Inc. (0001826457) (Issuer)
• 52d
  Principal Accounting Officer Dunn Edmund sold $2,496 worth of shares (139 units at $17.96), decreasing direct ownership by 0.61% to 22,554 units (SEC Form 4)

  4 - Monte Rosa Therapeutics, Inc. (0001826457) (Issuer)
• 53d
  President & CEO Warmuth Markus sold $97,974 worth of shares (5,466 units at $17.92), decreasing direct ownership by 0.88% to 613,471 units (SEC Form 4)

  4 - Monte Rosa Therapeutics, Inc. (0001826457) (Issuer)
• 55d
  Principal Accounting Officer Dunn Edmund exercised 25,700 shares at a strike of $13.41 and sold $464,886 worth of shares (25,700 units at $18.09) (SEC Form 4)

  4 - Monte Rosa Therapeutics, Inc. (0001826457) (Issuer)
• 61d
  Chief Medical Officer Janku Filip sold $179,161 worth of shares (9,189 units at $19.50), decreasing direct ownership by 12% to 65,837 units (SEC Form 4)

  4 - Monte Rosa Therapeutics, Inc. (0001826457) (Issuer)
• 107d
  President & CEO Warmuth Markus sold $128,373 worth of shares (5,466 units at $23.49), decreasing direct ownership by 0.88% to 618,937 units (SEC Form 4)

  4 - Monte Rosa Therapeutics, Inc. (0001826457) (Issuer)
• 111d
  Chief Business & Legal Officer Nickson Philip was granted 28,000 shares and sold $47,861 worth of shares (3,155 units at $15.17), increasing direct ownership by 69% to 60,845 units (SEC Form 4)

  4 - Monte Rosa Therapeutics, Inc. (0001826457) (Issuer)
• 111d
  Chief Operating Officer Champoux Jennifer was granted 35,000 shares and sold $39,882 worth of shares (2,629 units at $15.17), increasing direct ownership by 108% to 62,371 units (SEC Form 4)

  4 - Monte Rosa Therapeutics, Inc. (0001826457) (Issuer)
• 111d
  Principal Accounting Officer Dunn Edmund sold $15,762 worth of shares (1,039 units at $15.17), decreasing direct ownership by 4% to 22,693 units (SEC Form 4)

  4 - Monte Rosa Therapeutics, Inc. (0001826457) (Issuer)
• 111d
  President & CEO Warmuth Markus was granted 90,000 shares and sold $153,748 worth of shares (10,135 units at $15.17), increasing direct ownership by 15% to 624,403 units (SEC Form 4)

  4 - Monte Rosa Therapeutics, Inc. (0001826457) (Issuer)
• 111d
  Chief Medical Officer Janku Filip was granted 31,000 shares and sold $47,861 worth of shares (3,155 units at $15.17), increasing direct ownership by 59% to 75,026 units (SEC Form 4)

  4 - Monte Rosa Therapeutics, Inc. (0001826457) (Issuer)
• 111d
  Chief Scientific Officer Townson Sharon was granted 35,000 shares and sold $47,861 worth of shares (3,155 units at $15.17), increasing direct ownership by 88% to 67,845 units (SEC Form 4)

  4 - Monte Rosa Therapeutics, Inc. (0001826457) (Issuer)
• 314d
  SEC Form 4 filed by Director Behbahani Ali

  4 - Monte Rosa Therapeutics, Inc. (0001826457) (Issuer)
• 314d
  SEC Form 4 filed by Director Hughes Eric A

  4 - Monte Rosa Therapeutics, Inc. (0001826457) (Issuer)
• 314d
  SEC Form 4 filed by Director Siu Christine

  4 - Monte Rosa Therapeutics, Inc. (0001826457) (Issuer)
• 314d
  SEC Form 4 filed by Director Skvarka Jan

  4 - Monte Rosa Therapeutics, Inc. (0001826457) (Issuer)
• 314d
  SEC Form 4 filed by Director Schiff Andrew N

  4 - Monte Rosa Therapeutics, Inc. (0001826457) (Issuer)
• 314d
  SEC Form 4 filed by Director Manning Anthony M.

  4 - Monte Rosa Therapeutics, Inc. (0001826457) (Issuer)
• 314d
  SEC Form 4 filed by Director Blackwell Kimberly

  4 - Monte Rosa Therapeutics, Inc. (0001826457) (Issuer)
• 326d
  Principal Accounting Officer Dunn Edmund sold $9,174 worth of shares (2,062 units at $4.45), decreasing direct ownership by 8% to 23,732 units (SEC Form 4)

  4 - Monte Rosa Therapeutics, Inc. (0001826457) (Issuer)
• 475d
  Chief Business & Legal Officer Nickson Philip was granted 36,000 shares (SEC Form 4)

  4 - Monte Rosa Therapeutics, Inc. (0001826457) (Issuer)
• 475d
  Principal Accounting Officer Dunn Edmund was granted 11,850 shares, increasing direct ownership by 85% to 25,794 units (SEC Form 4)

  4 - Monte Rosa Therapeutics, Inc. (0001826457) (Issuer)
• 475d
  Chief Medical Officer Janku Filip was granted 36,000 shares, increasing direct ownership by 392% to 45,189 units (SEC Form 4)

  4 - Monte Rosa Therapeutics, Inc. (0001826457) (Issuer)
• 475d
  Chief Scientific Officer Townson Sharon was granted 36,000 shares (SEC Form 4)

  4 - Monte Rosa Therapeutics, Inc. (0001826457) (Issuer)
• 475d
  President & CEO Warmuth Markus was granted 128,000 shares, increasing direct ownership by 31% to 544,538 units (SEC Form 4)

  4 - Monte Rosa Therapeutics, Inc. (0001826457) (Issuer)
• 475d
  Chief Operating Officer Champoux Jennifer was granted 30,000 shares (SEC Form 4)

  4 - Monte Rosa Therapeutics, Inc. (0001826457) (Issuer)
• 499d
  SEC Form 4 filed by Director Hughes Eric A

  4 - Monte Rosa Therapeutics, Inc. (0001826457) (Issuer)
• 543d
  Large owner Versant Venture Capital Vi, L.P. sold $1,491,041 worth of shares (157,895 units at $9.44), disposed of 1,435,402 shares and acquired 48,945 shares (SEC Form 4)

  4 - Monte Rosa Therapeutics, Inc. (0001826457) (Issuer)
• 579d
  Large owner Versant Venture Capital Vi, L.P. sold $7,395,203 worth of shares (1,132,566 units at $6.53) (SEC Form 4)

  4 - Monte Rosa Therapeutics, Inc. (0001826457) (Issuer)
• 590d
  Large owner Versant Venture Capital Vi, L.P. sold $3,404,791 worth of shares (567,213 units at $6.00) (SEC Form 4)

  4 - Monte Rosa Therapeutics, Inc. (0001826457) (Issuer)
• 590d
  SEC Form 4 filed by Chief Medical Officer Janku Filip

  4 - Monte Rosa Therapeutics, Inc. (0001826457) (Issuer)
• 656d
  Principal Accounting Officer Dunn Edmund sold $6,166 worth of shares (1,610 units at $3.83), decreasing direct ownership by 10% to 13,944 units (SEC Form 4)

  4 - Monte Rosa Therapeutics, Inc. (0001826457) (Issuer)
• 682d
  SEC Form 4 filed by Director Behbahani Ali

  4 - Monte Rosa Therapeutics, Inc. (0001826457) (Issuer)
• 682d
  SEC Form 4 filed by Director Schiff Andrew N

  4 - Monte Rosa Therapeutics, Inc. (0001826457) (Issuer)
• 682d
  SEC Form 4 filed by Director Skvarka Jan

  4 - Monte Rosa Therapeutics, Inc. (0001826457) (Issuer)
• 682d
  SEC Form 4 filed by Director Siu Christine

  4 - Monte Rosa Therapeutics, Inc. (0001826457) (Issuer)
• 682d
  SEC Form 4 filed by Director Manning Anthony M.

  4 - Monte Rosa Therapeutics, Inc. (0001826457) (Issuer)
• 682d
  SEC Form 4 filed by Director Blackwell Kimberly

  4 - Monte Rosa Therapeutics, Inc. (0001826457) (Issuer)
• 690d
  SEC Form 4 filed by Nickson Philip

  4 - Monte Rosa Therapeutics, Inc. (0001826457) (Issuer)
• 690d
  Dunn Edmund sold $4,876 worth of shares (1,207 units at $4.04), decreasing direct ownership by 7% to 15,554 units (SEC Form 4)

  4 - Monte Rosa Therapeutics, Inc. (0001826457) (Issuer)
• 690d
  SEC Form 4 filed by Townson Sharon

  4 - Monte Rosa Therapeutics, Inc. (0001826457) (Issuer)
• 690d
  SEC Form 4 filed by Champoux Jennifer

  4 - Monte Rosa Therapeutics, Inc. (0001826457) (Issuer)
• 843d
  SEC Form 4 filed by Wallace Owen B.

  4 - Monte Rosa Therapeutics, Inc. (0001826457) (Issuer)
• 843d
  SEC Form 4 filed by Warmuth Markus

  4 - Monte Rosa Therapeutics, Inc. (0001826457) (Issuer)
• 843d
  SEC Form 4 filed by Jones Jullian G

  4 - Monte Rosa Therapeutics, Inc. (0001826457) (Issuer)
• 843d
  SEC Form 4 filed by Dunn Edmund

  4 - Monte Rosa Therapeutics, Inc. (0001826457) (Issuer)
• 843d
  SEC Form 4 filed by Janku Filip

  4 - Monte Rosa Therapeutics, Inc. (0001826457) (Issuer)
• 843d
  SEC Form 4 filed by Nickson Philip

  4 - Monte Rosa Therapeutics, Inc. (0001826457) (Issuer)
• 1046d
  SEC Form 4 filed by Behbahani Ali

  4 - Monte Rosa Therapeutics, Inc. (0001826457) (Issuer)
• 1046d
  SEC Form 4 filed by Siu Christine

  4 - Monte Rosa Therapeutics, Inc. (0001826457) (Issuer)
• 1046d
  SEC Form 4 filed by Skvarka Jan

  4 - Monte Rosa Therapeutics, Inc. (0001826457) (Issuer)
• 1046d
  SEC Form 4 filed by Schiff Andrew N

  4 - Monte Rosa Therapeutics, Inc. (0001826457) (Issuer)
• 1046d
  SEC Form 4 filed by Mayweg Alexander

  4 - Monte Rosa Therapeutics, Inc. (0001826457) (Issuer)
• 1046d
  SEC Form 4 filed by Blackwell Kimberly

  4 - Monte Rosa Therapeutics, Inc. (0001826457) (Issuer)
• 1122d
  SEC Form 4 filed by Skvarka Jan

  4 - Monte Rosa Therapeutics, Inc. (0001826457) (Issuer)
• 1208d
  SEC Form 4 filed by Wallace Owen B.

  4 - Monte Rosa Therapeutics, Inc. (0001826457) (Issuer)
• 1208d
  SEC Form 4 filed by Jones Jullian G

  4 - Monte Rosa Therapeutics, Inc. (0001826457) (Issuer)
• 1208d
  SEC Form 4 filed by Nickson Philip

  4 - Monte Rosa Therapeutics, Inc. (0001826457) (Issuer)

Other GLUE categories

• 8-K
• 10-K
• 10-Q
• S-1
• 13D
• 13G
• Form 3
• Form 5
• DEF 14A
• M&A
• Earnings
• Dividends